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The Role of Radiopharmaceuticals MIBG and (V) DMSA in the 
Diagnosis of Medullary Thyroid Carcinoma 
Uberta Verga,* Fabrizio Muratori,* Gianleone Di Sacco,* Francesco Banfi,* 
and Alfonso Libroia* 
The diagnostic value of'""-"I meta-iodo-benzylguanidine (MIBG) and ''''"'Tc (V) dimercaptosuccinic 
acid (DMSA) was investigated in 12 patients with proven medullary thyroid carcinoma (MTC). 
Scintigraphic imaging with DMSA was negalive in nine of 12 patients. Scintigraphy with MIBG was 
positive in only one case. In proven primary or recurrent disease, DMSA sensitivity was 50% and 
MIBG .sensitivity was 25%. Such sensitivities become much lower in subjects wilh high calcitonin (CT) 
levels who have had negative surgical explorations: DMSA 17% and MIBG 0%. DMSA delected tumor 
in 25% of the patients and MIBG in only 8%. The positivity of these scintigraphies appears to be 
unrelated to carcinoembryonic antigen and CT plasma levels. Such data suggest that .scintigraphies 
wilh MIBG and DMSA are only modestly useful in the diagnosis of MTC. (Henry Ford Hosp Med J 
1989:37:175-7) 
In the follow-up of patients treated by total thyroidectomy for medullary thyroid carcinoma (MTC), the presence of high 
baseline calcitonin (CT) levels and/or remarkably increased CT 
tevels after calcium or pentagastrin infusion represent evidence 
of recunent disease. The tumor may metastasize locally or to 
bones and soft tissue (1); such metastases are difficult to detect 
with the commonly available techniques. To localize tumor re-
cunence, various imaging methods have been used, including 
ultrasound and axial computed tomography. Several reports 
have suggested a potential diagnostic and therapeutic role of ' " I 
meta-iodo-benzylguanidine (MIBG) in MTC (2). The radioiodi-
nated MIBG uptake in MTC is not surprising because C-celts 
originate from the ectodermal neural crest as do many ofthe 
other neoplasms imaged with this agent. The most encouraging 
results seem to be offered by ""Tc (V) dimercaptosuccinic acid 
(DMSA) which accumulates in the tumor and metastatic sites. 
Nevertheless, several authors report conflicfing data (3,4). To 
gain further knowledge regarding the use of MIBG and DMSA, 




Twelve patients, four females and eight males aged 11 to 67, 
were studied. Five patients belonged to two muttiple endocrine 
neoplasia type 2A (MEN 2A) families and seven had sporadic 
MTC. Of the 11 patients with elevated basal plasma CT levels, 
ten had previously undergone total thyroidectomy and 
lymphadenectomy and one was studied both before and after 
partial ablation of the neoplastic masses in the neck. The twelfth 
patient, a member of a MEN 2A family, had not yet had total 
thyroidectomy and showed high CT seram levets only after cal-
cium and pentagastrin stimulation. Nine of the 12 subjects atso 
showed elevated carcinoembryonic antigen (CEA) levels. 
CT and CEA measurement 
The quantitative determination of CT in serum was measured 
using a radioimmunologic method (RIA-mat Calcitonin I I , 
Byk-Santec Diagnostica Dietzenbach, RFA). CEA values 
were defined using a monoclonal radioimmunologic method 
(Ammerwell CEA Assay monoclonal Amersham). The nonnal 
values were below 150 pg/mL for seram CT levels and below 5 
ng/mL for plasma CEA levels. 
MIBG 
MIBG scintigraphies were performed after an intravenous 
injection of 90 MBq of " ' I MIBG or 185 MBq of '^^ MIBG. 
Imaging with " ' I MIBG was performed at 24 and 48 hours and 
with '-T MIBG at 4 and 24 hours after. All patients received 
blocking doses of Lugol's iodine solution orally (60 mg po-
tassium iodide twice daily beginning two days before the start of 
the study and continuing throughout its duration). 
DMSA 
Two commerciat kits of Tc (V) DMSA were obtained using 
controlled atkalination of the Tc(III) DMSA mixture commonly 
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-
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- -
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9 65 S/R • 7.2 223 3-t 3- -
in 42 S/R 3- 11.0 274 
- -
I I 19 M/R 3- >60 410 - -
12 ; i i M/R 3- 0.9 258 
-
'' For norniul values sec text. 
' Mainlained positivity after partial ablation of tumor mass. 
tAt'ter scintigraphy investigalinn. 
S - sporadic. M ^ MEN 2A. P = primary lutDor. R = recurrent disease. 
used for kidney scanning. DMSA scintigraphies were per-
formed two to three hours after an intravenous administration of 
370 to 444 MBq of "'"Tc (V) DMSA. Quality control of ""Tc 
(V) DMSA at the time of preparation ensured that the material 
administered was alkaline (pH 8 to 8.5). 
These scintigraphies were performed using a large field of 
view gamma camera with high resolution collimator interfaced 
to a data processor The two types of scintigraphies were per-
formed within a one-month period. 
Results 
Nine of 12 scintigraphic imagings with DMSA gave negative 
responses, while scintigraphy with MIBG was positive in only 
one case (Table). Both DMSA and MIBG gave positive re-
sponses only in the patient with the priinary tumor. This patient 
had a large mass in the neck area which was positive to scintigra-
phy with both tracers before and after partial ablation. The two 
subjects who were positive with DMSA but not with MIBG had 
recurrent disease, one with histologically positive lateral cer-
vical lymph nodes and one with uptake in the tenth left rib and 
skull. Computed axial tomography confirmed the presence ofa 
rib lesion. Two of the nine subjects with negative responses to 
DMSA and MIBG had histologically positive lateral cervical 
masses; one was the only patient who showed an accumulation 
in the renal areas. A third subject had two intrathyroid neo-
plastic foci. The positivity of these scintigraphies did not cone-
late with CEA and CT plasma levels. 
Discussion 
The diagnosis of MTC recurrence is based on the assay of 
plasma CT and CEA levels because high CT levels are known to 
be related to residual tumor or recunences (5) and elevated 
plasma CEA levels often indicate more aggressive tumors (6). 
However, traditional imaging techniques do not have high sen-
sitivity in localizing residual tumor Scanning with """Tc (V) 
DMSA and " ' I MIBG has been proposed. MIBG, an analog of 
the adrenergic blocking agent, has been used for the localization 
of pheochromocytoma and may accumulate in MTC as well (7). 
The mechanism of (V) DMSA concentration in neoplastic sites 
is not clear The nonspecific accumulation of this radiotracer in 
the neoplastic sites may be related to local abnormalities of 
phosphorus and calcium metabolism (8). Most reports show a 
much lower diagnostic efficacy for MIBG in comparison with 
DMSA (9). However, MIBG has a potential therapeutic role in 
MTC (10). 
Guerra et al (11), reporting the data available in literature, 
showed that DMSA sensitivity is about 80% for primary tumors 
and 68% for recurrent diseases. Although these data seem en-
couraging, the investigations have mainly involved subjects 
with tumoral lesions already evident. In the 12 subjects of our 
study, one true positive was observed with MIBG, three true 
positives with DMSA, and no false-posifives. Other investiga-
tions identified tumoral lesions in six of the 12 patients. By con-
sidering only those patients who presented with primary tumors 
or recunent disease already proven at the time of scintigraphic 
investigation (pafients 1 to 4), DMSA sensitivity is 50% (or 66% 
not considering patient 2 with tracer kidney uptake) and MIBG 
sensitivity is 25%. Such sensitivities are much lower when con-
sidering those subjects with high CT levels and other negative 
invesfigation (all 12 subjects); DMSA 25% and MIBG 8%. In 
subjects with high CT levels and negative explorations (patients 
5 to 12). DMSA sensitivity is about 17% and MIBG 0%. 
Our data show that DMSA and MIBG scintigraphies can 
efficaciously identify tumor lesions that are already evident and 
have a much lower sensitivity when such lesions are not ob-
vious. These scintigraphic approaches are of only modest utility 
in the postoperative follow-up of MTC patients. However, 
MIBG is useful in the diagnosis of pheochromocytoma (12) and 
has a potential therapeutic role in MTC. A radioiodinated ana-
log of sandostatin ('-T-Iabeled tyr-3-octreoite) has been 
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recently investigated to label somatostatin receptors in endo-
crine-related tumors in vivo and to localize tumors that present 
membrane-bound somatostarin receptors (13). 
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